Home » Newsletters » BioWorld Asia

BioWorld Asia

July 12, 2000

View Archived Issues

Arrow Completes #11M Round For Antimicrobial Programs

EU Patent Plan Would Reduce Costs, Encourage Innovation

Drug-Resistant HIV Strains Arise Prior To Start Of Drug Treatment

Ontario Invests In Three Centers, Plans To Become Biotech Hub

Brandys Steps Down At Genset; Director Assumes Top Positions

British Biotech Changes Focus, Seeks To Move Past Marimastat

Roche, Atugen Collaborate To Study Gene Function In Vivo

UK Genetics Commission Plans Open Discussion On Principles

Israeli Biotech Companies Continue Moving Forward

Australian Investors Launch Biotechnology Venture Fund

Lion Bioscience Seeks $191M In IPO On Nasdaq, Neuer Markt

Prodi Recognizes EU Need To Restore Confidence In Biotech

EPO Upholds CAT Patent On Phage Display Of Antibodies

NicOx Gets Positive Results In Early Dermatology Trial

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...